Get started
Relmada Therapeutics, Inc.Relmada Therapeutics, Inc.Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

RLMD chart


Full chart

RLMD upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪21.41 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.6516 USD
Net income (FY)
‪−79.98 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪27.81 M‬
Beta (1Y)
2.97

Employees


Employees (FY)
17
Change (1Y)
−3 −15.00%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−4.70 M‬ USD

About Relmada Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Sergio Traversa
Website
relmada.com
Headquarters
Coral Gables
Founded
2012
FIGI
BBG003MKSL16
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

RLMD news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as RLMD.

Frequently Asked Questions


The current price of RLMD is 0.6451 USD — it has decreased by −12.51% in the past 24 hours. Watch Relmada Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Relmada Therapeutics, Inc. stocks are traded under the ticker RLMD.
RLMD stock has risen by 122.22% compared to the previous week, the month change is a 101.59% rise, over the last year Relmada Therapeutics, Inc. has showed a −82.98% decrease.
We've gathered analysts' opinions on Relmada Therapeutics, Inc. future price: according to them, RLMD price has a max estimate of 1.00 USD and a min estimate of 1.00 USD. Watch RLMD chart and read a more detailed Relmada Therapeutics, Inc. stock forecast: see what analysts think of Relmada Therapeutics, Inc. and suggest that you do with its stocks.
RLMD reached its all-time high on Jun 25, 2020 with the price of 54.0000 USD, and its all-time low was 0.2404 USD and was reached on Mar 3, 2025. View more price dynamics on RLMD chart.
See other stocks reaching their highest and lowest prices.
RLMD stock is 29.35% volatile and has beta coefficient of 2.97. Track Relmada Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Relmada Therapeutics, Inc. there?
Today Relmada Therapeutics, Inc. has the market capitalization of ‪24.47 M‬, it has decreased by −1.93% over the last week.
Yes, you can track Relmada Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Relmada Therapeutics, Inc. is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
RLMD earnings for the last quarter are −0.62 USD per share, whereas the estimation was −0.67 USD resulting in a 7.92% surprise. The estimated earnings for the next quarter are −0.48 USD per share. See more details about Relmada Therapeutics, Inc. earnings.
Relmada Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
RLMD net income for the last quarter is ‪−18.66 M‬ USD, while the quarter before that showed ‪−21.73 M‬ USD of net income which accounts for 14.13% change. Track more Relmada Therapeutics, Inc. financial stats to get the full picture.
No, RLMD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 26, 2025, the company has 17 employees. See our rating of the largest employees — is Relmada Therapeutics, Inc. on this list?
Like other stocks, RLMD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Relmada Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Relmada Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Relmada Therapeutics, Inc. stock shows the sell signal. See more of Relmada Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.